Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among Veterans

NCT07895134 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Efficacy, and Mechanisms of Psilocybin-assisted Acceptance and Commitment Therapy (PACT) in Treating Major Depressive Disorder (MDD) Among Veterans
Lead sponsor
VA Office of Research and Development
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2031
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

major depression

Arms

As registered; 8 arms.

  • Psilocybin, modafanil, zolpidem, pimavanserin arm ExperimentalPsilocybin, modafinil, pimavanserin, zolpidem

    Participants will receive a single dose of 1-30mg of psilocybin, in addition to 3 other drugs: modafinil, zolpidem, pimavanserin. All participants will be masked to the probability of being assigned to a specific arm

  • Psilocybin, modafanil, zolpidem arm ExperimentalPsilocybin, modafinil, zolpidem

    Participants will receive a single dose of 1-30mg of psilocybin, in addition to 2 other drugs: modafinil and zolpidem and placebo. All participants will be masked to the probability of being assigned to a specific arm

  • Psilocybin, modafanil, pimavanserin arm ExperimentalPsilocybin, modafinil, pimavanserin

    Participants will receive a single dose of 1-30mg of psilocybin, in addition to 2 other drugs: modafinil, pimavanserin, and placebo. All participants will be masked to the probability of being assigned to a specific arm

  • Psilocybin, modafanil arm ExperimentalPsilocybin, modafinil

    Participants will receive a single dose of 1-30mg of psilocybin, in addition to 1 other drug: modafinil, and placebo. All participants will be masked to the probability of being assigned to a specific arm

  • Psilocybin, zolpidem, arm ExperimentalPsilocybin, zolpidem

    Participants will receive a single dose of 1-30mg of psilocybin, in addition to 1 other drug: zolpidem, and placebo. All participants will be masked to the probability of being assigned to a specific arm

+3 more arms

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Hamilton Depression Rating Scale-6 (HAMD-6) Baseline to 30 and 90 days post-drug administration

    A clinician-administered, 6-item version of the Hamilton Depression Rating Scale that assesses core depressive symptoms including depressed mood, guilt, work and activities, psychomotor retardation, psychic anxiety, and somatic symptoms. Scores range from 0-22, with higher scores indicating greater depression severity. Administered at Baseline, Day 1, Day 7, Day 30, and Day 90.

Lead sponsor's other trials

VA Office of Research and Development, most recent start first.

Similar trials

Same condition (Major Depressive Disorder) and phase, most recent start first.